JP2016501843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501843A5 JP2016501843A5 JP2015540216A JP2015540216A JP2016501843A5 JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5 JP 2015540216 A JP2015540216 A JP 2015540216A JP 2015540216 A JP2015540216 A JP 2015540216A JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- lymphoma
- fragments
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1220010.1 | 2012-11-07 | ||
| GBGB1220010.1A GB201220010D0 (en) | 2012-11-07 | 2012-11-07 | Therapeutic amd diagnostic target |
| PCT/GB2013/052899 WO2014072700A1 (en) | 2012-11-07 | 2013-11-06 | Ly75 as cancer therapeutic and diagnostic target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Division JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501843A JP2016501843A (ja) | 2016-01-21 |
| JP2016501843A5 true JP2016501843A5 (enExample) | 2016-11-24 |
Family
ID=47429281
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540216A Pending JP2016501843A (ja) | 2012-11-07 | 2013-11-06 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150297743A1 (enExample) |
| EP (1) | EP2917239A1 (enExample) |
| JP (4) | JP2016501843A (enExample) |
| KR (1) | KR102256552B1 (enExample) |
| CN (2) | CN104755496A (enExample) |
| AU (2) | AU2013343277B2 (enExample) |
| BR (1) | BR112015009438B1 (enExample) |
| CL (1) | CL2015001098A1 (enExample) |
| EA (1) | EA033649B1 (enExample) |
| GB (1) | GB201220010D0 (enExample) |
| HK (1) | HK1214611A1 (enExample) |
| NZ (1) | NZ707116A (enExample) |
| SG (2) | SG10201810357WA (enExample) |
| UA (1) | UA117569C2 (enExample) |
| WO (1) | WO2014072700A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| SG11201602460QA (en) | 2013-10-11 | 2016-04-28 | Oxford Biotherapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
| AU2016269632B2 (en) * | 2015-05-29 | 2021-09-09 | Mla Diagnostics B.V. | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis |
| KR101796091B1 (ko) | 2016-05-02 | 2017-11-10 | 충남대학교 산학협력단 | 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CN109685135B (zh) * | 2018-12-21 | 2022-03-25 | 电子科技大学 | 一种基于改进型度量学习的少样本图像分类方法 |
| EP4065599A4 (en) * | 2019-11-26 | 2023-11-01 | Cedars-Sinai Medical Center | COMPOSITIONS AND METHODS FOR TREATING ILLNESSES AND CONDITIONS BY REMOVING MITOCHONDRIAL OR GENOMIC DNA FROM THE CIRCULATION |
| JPWO2023032995A1 (enExample) | 2021-08-31 | 2023-03-09 | ||
| CN117642413A (zh) | 2021-08-31 | 2024-03-01 | 富士胶片株式会社 | 化合物及使用了该化合物的标记生物物质 |
| WO2023032996A1 (ja) | 2021-08-31 | 2023-03-09 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| MX2024003132A (es) * | 2021-09-13 | 2024-04-10 | Regeneron Pharma | Metodos para tratar la hematopoyesis clonal de potencial indeterminado (chip) con inhibidores del antigeno linfocitario 75 (ly75), grupo de diferenciacion 164 (cd164) o poli (adp-ribosa) polimerasa 1 (parp1). |
| EP4644874A1 (en) | 2022-12-26 | 2025-11-05 | FUJIFILM Corporation | Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit |
| JPWO2024181455A1 (enExample) | 2023-02-27 | 2024-09-06 | ||
| WO2024181454A1 (ja) | 2023-02-27 | 2024-09-06 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| WO2025047686A1 (ja) | 2023-08-31 | 2025-03-06 | 富士フイルム株式会社 | 標的化薬物複合体及びこれを含む医薬、並びに、化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| EP1015489B1 (en) * | 1996-05-29 | 2006-07-05 | Derek Nigel John Hart | Dendritic cell receptor |
| AU2002237972B2 (en) * | 2001-01-31 | 2007-11-29 | Biogen Idec Inc. | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| CA2689974A1 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| KR101811965B1 (ko) * | 2007-11-07 | 2017-12-22 | 셀덱스 쎄라퓨틱스, 인크. | 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체 |
| EP2159291A1 (en) * | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
| CA2813494A1 (en) * | 2009-10-08 | 2011-04-14 | President And Fellows Of Harvard College | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| JP6431104B2 (ja) * | 2017-02-27 | 2018-11-28 | オリコン株式会社 | マイクロ波を利用した金属蒸気の発生方法 |
-
2012
- 2012-11-07 GB GBGB1220010.1A patent/GB201220010D0/en not_active Ceased
-
2013
- 2013-06-11 UA UAA201504407A patent/UA117569C2/uk unknown
- 2013-11-06 NZ NZ707116A patent/NZ707116A/en unknown
- 2013-11-06 JP JP2015540216A patent/JP2016501843A/ja active Pending
- 2013-11-06 CN CN201380056271.2A patent/CN104755496A/zh active Pending
- 2013-11-06 CN CN202110466746.1A patent/CN113181372A/zh active Pending
- 2013-11-06 HK HK16102576.0A patent/HK1214611A1/zh unknown
- 2013-11-06 AU AU2013343277A patent/AU2013343277B2/en active Active
- 2013-11-06 SG SG10201810357WA patent/SG10201810357WA/en unknown
- 2013-11-06 BR BR112015009438-4A patent/BR112015009438B1/pt active IP Right Grant
- 2013-11-06 KR KR1020157011701A patent/KR102256552B1/ko active Active
- 2013-11-06 EP EP13789381.4A patent/EP2917239A1/en active Pending
- 2013-11-06 WO PCT/GB2013/052899 patent/WO2014072700A1/en not_active Ceased
- 2013-11-06 SG SG11201503363WA patent/SG11201503363WA/en unknown
- 2013-11-06 EA EA201590694A patent/EA033649B1/ru unknown
- 2013-11-06 US US14/440,483 patent/US20150297743A1/en not_active Abandoned
-
2015
- 2015-04-27 CL CL2015001098A patent/CL2015001098A1/es unknown
-
2018
- 2018-05-17 AU AU2018203478A patent/AU2018203478B2/en active Active
- 2018-07-27 JP JP2018141190A patent/JP7079685B2/ja active Active
-
2019
- 2019-04-24 US US16/392,796 patent/US20190317100A1/en not_active Abandoned
-
2020
- 2020-09-14 JP JP2020154083A patent/JP2021011483A/ja active Pending
- 2020-11-18 US US16/951,023 patent/US20210346512A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022177986A patent/JP7479435B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dogan et al. | B-cell maturation antigen expression across hematologic cancers: a systematic literature review | |
| NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target | |
| CY1124634T1 (el) | Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2010518847A5 (enExample) | ||
| JP2011509079A5 (enExample) | ||
| JP2016500110A5 (enExample) | ||
| EA201691144A1 (ru) | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка | |
| JP2017501137A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| JP2014530877A5 (enExample) | ||
| JP2008538289A5 (enExample) | ||
| JP2014513068A5 (enExample) | ||
| RU2018125490A (ru) | Нейтрализация ингибиторных путей в лимфоцитах | |
| JP2013507968A5 (enExample) | ||
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| JP2015514716A5 (enExample) | ||
| US20150361504A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| JP2024502091A5 (enExample) | ||
| JP2016502091A5 (enExample) | ||
| ATE557276T1 (de) | Spezifisches verfahren zum krebsnachweis | |
| Afonso et al. | QCM immunoassay for recombinant cysteine peptidase: A potential protein biomarker for diagnosis of citrus canker | |
| JP2010535506A5 (enExample) | ||
| JP2015523852A5 (enExample) | ||
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo |